Phase 3 CERVINO Trial Shows Etentamig Significantly Improves Response Rate and Progression-Free Survival in Relapsed/Refractory Myeloma Read more about Phase 3 CERVINO Trial Shows Etentamig Significantly Improves Response Rate and Progression-Free Survival in Relapsed/Refractory MyelomaAdd new comment
August 2026 – Myeloma News from the Journals Read more about August 2026 – Myeloma News from the JournalsAdd new comment
The International Myeloma Foundation Wants You to #KnowMyeloma for Blood Cancer Awareness Month 2026 Read more about The International Myeloma Foundation Wants You to #KnowMyeloma for Blood Cancer Awareness Month 2026 Add new comment
IMF Chairperson of the Board Dr. S. Vincent Rajkumar and IMF SAB Member Dr. Shaji Kumar Co-Author Study on 'Redefining Plasma Cell Leukemia' Read more about IMF Chairperson of the Board Dr. S. Vincent Rajkumar and IMF SAB Member Dr. Shaji Kumar Co-Author Study on 'Redefining Plasma Cell Leukemia'Add new comment
European Commission Approves Tecvyali (teclistamab) in Combination with Daratumumab for Relapsed/Refractory Multiple Myeloma Read more about European Commission Approves Tecvyali (teclistamab) in Combination with Daratumumab for Relapsed/Refractory Multiple MyelomaAdd new comment
FDA Grants Accelerated Approval to Iberdomide in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone as Treatment for Relapsed/Refractory Myeloma Read more about FDA Grants Accelerated Approval to Iberdomide in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone as Treatment for Relapsed/Refractory Myeloma Add new comment
IMWG Awards Dinner Celebrates Two Luminaries in Myeloma Research Read more about IMWG Awards Dinner Celebrates Two Luminaries in Myeloma Research Add new comment
Positive Topline Results from the Phase 3 MonumenTAL-6 Trial: Teclistamab Plus Talquetamab, Talquetamab Plus Pomalidomide Improved PFS and OS vs Standard of Care in RRMM Read more about Positive Topline Results from the Phase 3 MonumenTAL-6 Trial: Teclistamab Plus Talquetamab, Talquetamab Plus Pomalidomide Improved PFS and OS vs Standard of Care in RRMMAdd new comment
July 2026 – Myeloma News from the Journals Read more about July 2026 – Myeloma News from the JournalsAdd new comment
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act Read more about Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity ActAdd new comment
